AlphAIAlphAI — Financial news for AI agents
Stock TitanMAR 33 min read$ATYR

ATYR Financials: Income Statement, Balance Sheet & Cash Flow

This article provides a detailed financial overview of Atyr Pharma Inc (ATYR), including its income statement, balance sheet, and cash flow statement, along with key financial ratios. It highlights the company's financial health signals, annual and quarterly metrics, and frequently asked questions about its performance. The analysis indicates weak overall financial health with low profitability and negative cash flow, despite strong liquidity and low leverage.

Original reporting
Stock Titan
Published Mar 3, 2026, 8:51 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Mar 3, 2026, 8:56 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
ATYR Financials: Income Statement, Balance Sheet & Cash Flow — source image
Source · Stock Titan
Decision brief

The 30-second read

$ATYRBearishLow
01

Why it matters

Financial weakness may lead to further stock decline, affecting investor confidence and sector perception.

02

Market read

Financial data indicates limited short-term trading opportunities; more relevant for long-term risk assessment.

03

What to watch

Potential upcoming catalysts or partnership news not reflected in current financials could alter outlook.

Relevance 6/10Timing: Limited short-term trading relevance; primarily long-term concern.

Background

Recent financial statements reveal ongoing challenges for ATYR, including low profitability and negative cash flow, despite liquidity.

Company-level read

Ticker impact

$ATYRBearishMedium confidence
Context

High relevance due to direct financial data impact.

Expected impact

Potential further decline in stock price due to ongoing financial struggles.

Evidence & confidence

The analysis is based on recent financial reports indicating poor profitability and cash flow issues, which historically correlate with downward price movements. However, lack of current market price data limits precision.

Market effects

Sector

Weak financials in biotech/life sciences sector may pressure sector indices.

Regional

Limited regional impact; company-specific issue.

Global

Minimal global market relevance; focused on company fundamentals.

Counterpoint

What could challenge this read

If company management implements strategic turnaround, stock could stabilize or improve over the medium term.

Key entities

  • Company
    Atyr Pharma Inc

    Biotech company focusing on rare disease treatments.

Read at source← All news

Related articles

OCT 13
$ATYRMedAI 8/10

aTyr Pharma publishes ATYR0101 anti-fibrotic study results

aTyr Pharma (NASDAQ:ATYR) published research on its experimental therapy ATYR0101 in the Journal of Biological Chemistry. The study showed ATYR0101 reduced collagen content and Ashcroft score in a lung fibrosis model, outperforming nintedanib. The company plans to advance ATYR0101 into clinical trials in 2027. ATYR0101 targets fibrosis by inducing myofibroblast apoptosis, according to the research.

investing.com2 min
SEP 24
$ATYRMedAI 8/10

Positive FDA Alignment Boosts ATyr Pharma's Rare Lung Disease - aTyr Pharma (NASDAQ:ATYR)

aTyr Pharma (NASDAQ:ATYR) reached an agreement with the FDA on the Phase 3 study protocol for efzofitimod, a treatment for pulmonary sarcoidosis. The trial will enroll 372 patients and evaluate lung function and patient-reported outcomes. The company needs additional funding and has $58.9M in cash as of June 30. Shares were down 6.08% to $0.35 at the time of publication.

benzinga.com2 min
SEP 24
$ATYRMedAI 8/10

ATYR Stock In Focus After FDA Alignment On Efzofitimod Phase 3

aTyr Pharma (ATYR) aligned with the FDA on a Phase 3 study for efzofitimod in pulmonary sarcoidosis. The 54-week trial will enroll 372 patients, with primary and secondary endpoints focused on lung function and quality of life. The company plans to begin the trial in Q4 2026 and may seek additional financing. ATYR stock is currently at $0.36, down 4.42%.

rttnews.com2 min
SEP 24
$ATYRHighAI 8/10

Why is aTyr Pharma stock surging today?

aTyr Pharma (ATYR) stock rose 9.8% in pre-market trading after aligning with the FDA on a Phase 3 study protocol for efzofitimod, a treatment for pulmonary sarcoidosis. The trial, set to begin in Q4 2026, requires additional financing. CEO Sanjay Shukla highlighted the milestone, though the company faces execution risks. The move contrasts with broader market declines.

investing.com2 min
SEP 24
$ATYRHighAI 8/10

Why is aTyr Pharma stock rallying today?

aTyr Pharma (ATYR) stock rose 9.1% in pre-market trading after aligning with the FDA on a Phase 3 study protocol for efzofitimod, its lead therapeutic candidate. The study, expected to start in Q4 2026, will evaluate efzofitimod in patients with pulmonary sarcoidosis. The company's stock has faced uncertainty but maintains a Buy rating from analysts.

investing.com2 min
SEP 24
$ATYRMedAI 8/10

ATyr Pharma, Inc. (the Company) announced that it has reached alignment with the U.S. Food and Drug Administration (FDA) on the protocol for a Phase 3 study…

aTYR PHARMA INC (ATYR) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On September 24, 2026, aTyr Pharma, Inc. (the Company) announced that it has reached alignment with the U.S. Food and Drug Administration (FDA) on the protocol for a Phase 3 study of its lead therapeutic candidate, efzofitimod, in patients with chronic, sy

SEC EDGAR 8-K2 min